Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

CAR-Multicenter-Analyse (CAR-MA): Retrospektive Studie zur Charakterisierung von CAR-T-Zell-Ergebnissen und verwandten Toxizitäten bei Kindern und jungen Erwachsenen mit B-ALL

23. Oktober 2026 aktualisiert von: National Cancer Institute (NCI)

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.

To evaluate the response of extramedullary disease following CAR T-cell therapy.

To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Detaillierte Beschreibung

Study Description:

This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.

Objectives:

Primary

  • To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

Secondary

  • To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
  • To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
  • To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
  • To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
  • To evaluate the response of extramedullary disease following CAR T-cell therapy.
  • To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
  • To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
  • To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
  • To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
  • To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
  • To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

57

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Maryland
      • Bethesda, Maryland, Vereinigte Staaten, 20892
        • National Cancer Institute (NCI)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

3 Jahre bis 25 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.

Beschreibung

  • Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: RETROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
1

Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Response free survival (completed)
Zeitfenster: 6 months

To evaluate the RFS at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab.

6 months
Outcome evaluation
Zeitfenster: 12 months

To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL

12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Complete Response Rate (completed)
Zeitfenster: 12 months

To evaluate the CR rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Relapse Rate (completed)
Zeitfenster: 12 months

To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Response free survival (completed)
Zeitfenster: 12 months

To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Minimal Residual Disease detection (completed)
Zeitfenster: 12 months

To evaluate the MRD negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab

12 months
Impact of immunotherapies on CAR outcomes
Zeitfenster: 12 months

To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes

12 months
Cytopenias after CAR
Zeitfenster: 12 months

To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T cell outcomes

12 months
Response of extramedullary disease
Zeitfenster: 12 months

To evlauate the response of extramedullary disease following CAR T cell therapy

12 months
Frequency of malignant neoplasms
Zeitfenster: 12 months

To evaluate the response of extramedullary disease following CAR T cell therapy

12 months
Response, survival and toxicities in subpopulations
Zeitfenster: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.

12 months
Impact of next generation sequencing MRD and duration of B cell aplasia
Zeitfenster: 12 months

To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.

12 months
Frequency of infections
Zeitfenster: 12 months

To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.

12 months
Response, survival and toxicities after CAR
Zeitfenster: 12 months

To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy)

12 months
Compare toxicities and outcomes across CAR constructs
Zeitfenster: 12 months

To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.)

12 months
Impact of CAR on other health-related outcomes
Zeitfenster: 12 months

To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes

12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Sara K Silbert, M.D., National Cancer Institute (NCI)

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

14. Oktober 2021

Primärer Abschluss (Tatsächlich)

29. Oktober 2024

Studienabschluss (Tatsächlich)

29. Oktober 2024

Studienanmeldedaten

Zuerst eingereicht

29. Juni 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. Juni 2022

Zuerst gepostet (Tatsächlich)

30. Juni 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

26. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

23. Oktober 2026

Zuletzt verifiziert

22. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 10000651
  • 000651-C

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

All IPD recorded in the medical record will be shared with intramural investigators upon request.

IPD-Sharing-Zeitrahmen

Clinical data available during the study and indefinitely.

IPD-Sharing-Zugriffskriterien

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .